Avalo Therapeutics (NASDAQ:AVTX – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Avalo Therapeutics to related companies based on the strength of its institutional ownership, valuation, analyst recommendations, earnings, profitability, dividends and risk.
Earnings & Valuation
This table compares Avalo Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Avalo Therapeutics | $60,000.00 | -$78.26 million | -2.83 |
| Avalo Therapeutics Competitors | $688.58 million | $7.69 million | -18.30 |
Avalo Therapeutics’ peers have higher revenue and earnings than Avalo Therapeutics. Avalo Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Institutional & Insider Ownership
87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Avalo Therapeutics and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avalo Therapeutics | N/A | -34.21% | -29.84% |
| Avalo Therapeutics Competitors | -12,224.75% | -204.85% | -31.52% |
Analyst Recommendations
This is a summary of recent recommendations and price targets for Avalo Therapeutics and its peers, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avalo Therapeutics | 1 | 2 | 11 | 0 | 2.71 |
| Avalo Therapeutics Competitors | 9932 | 15324 | 45736 | 1605 | 2.54 |
Avalo Therapeutics presently has a consensus price target of $36.82, indicating a potential upside of 416.38%. As a group, “Biotechnology” companies have a potential upside of 133.30%. Given Avalo Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Avalo Therapeutics is more favorable than its peers.
Summary
Avalo Therapeutics beats its peers on 8 of the 12 factors compared.
Avalo Therapeutics Company Profile
Avalo Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated and inflammatory diseases. The company does not have marketed products and is centered on advancing drug candidates through clinical development. Its lead candidate, AVTX-009, is a monoclonal antibody that targets interleukin-1 beta (IL-1β), an inflammatory signaling protein. Avalo is developing the therapy for hidradenitis suppurativa, a chronic inflammatory skin disease, and has described potential applications in other inflammatory conditions.
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
